1. Use of a composition for the manufacture of a product for improving the control functions in a subject in need thereof, said composition comprising: i) one or more of uridine and cytidine or their salts, phosphates, acyl derivatives or esters and ii) a lipid fraction comprising at least one of docosahexaenoic acid (22: 6 DHA), eicosapentaenoic acid (20: 5, EPA), and docosapentaenoic acid (22: 5, DPA) or an ester efirov.2. Use of a composition for the manufacture of a product for treating a subject in need thereof, said composition comprising: i) one or more of uridine and cytidine or their salts, phosphates, acyl derivatives or esters and ii) a lipid fraction comprising at least one of docosahexaenoic acid (22: 6 DHA), eicosapentaenoic acid (20: 5, EPA), and docosapentaenoic acid (22: 5, DPA) or esters thereof, wherein said subject is tested to control funktsii.3. Use according to claim. 2, wherein the test control functions includes a test sequence from [TMT], preferably DKEFS-TMT.4. Use according to any one of claims. 1-3, in which the control functions include processing speed, cognitive and mental flexibility, attention, scanning and / or cognitive shift zadach.5. Use according to any one of claims. 1-3, wherein said subject suffers from cognitive disorders or memory disorders, cognitive or memory impairment disorders, such as age-associated memory impairment (AAMI), Alzheimers disease (AD), multiple sclerosis, vascular dementia, frontotemporal dementia, semantic dementia or dementia with Lewy bodies, and / or psy1. Применение композиции для изготовления продукта для улучшения управляющих функций у субъекта, нуждающегося в этом, причем указанная композиция содержит:i) один или несколько из уридина и цитидина или их солей, фосфатов, ацильных производных или сложных эфиров иii) липидную фракцию, содержащую по меньшей мере одну из докозагексаеновой кислоты (22:6 DHA), эйкозапентаеновой кислоты (20:5 ЕРА) и докозапентаеновой кислоты (22:5 DPA) или их сложных эфир
